Pharmacokinetics of pioglitazone, a thiazolidinedione derivative, in male Naeini (Iranian fat-tailed) sheep

Journal of Applied Animal Research

Volumn 40, Issue 3, 2012, Pages 208-214

  Ghoreishi, S M ^a   Rajaian, H ^b   Sheykhzade, M ^c   Alikhani, M ^a   Rahmani, H R ^a   Hajipour, A R ^a   Khorvash, M ^a   Khodaei, H R ^d  

^a ISFAHAN UNIVERSITY OF TECHNOLOGY   (Iran)

^b SHIRAZ UNIVERSITY   (Iran)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

bioavailability; pharmacokinetics; pioglitazone; sheep; thiazolidinedione

Indexed keywords

BOS; BOVIDAE; OVIS ARIES;

EID: 84864115437     PISSN: 09712119     EISSN: 09741844     Source Type: Journal    
DOI: 10.1080/09712119.2012.658061     Document Type: Article

References (25)

1. Bionaz M, Baumrucker CR, Shirk E, VandenHeuvel JP, Block E, Varga GA. 2008. Characterization of Madin-Darby bovine kidney cell line for peroxisome proliferator-activated receptors: temporal response and sensitivity to fatty acids. Journal of Dairy Science 91:2808-2813. (Pubitemid 351976602)
2. Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompor T, Eckland D. 2003. The pharmacokinetics of pioglitazone in patients with impaired renal function. British Journal of Clinical Pharmacology 55:368-374. (Pubitemid 36535367)
3. Eckland DA, Danhof M. 2000. Clinical pharmacokinetics of pioglitazone. Experimental and Clinical Endocrinology and Diabetes 108:S234-S242.
4. Fujita Y, Yamada Y, Kusama M, Yamauchi T, Kamon J, Kadowaki T, Iga T. 2003. Sex differences in thepharmacokinetics of pioglitazone in rats. Comparative Biochemistry Physiology Part C Toxicology Pharmacology 136:85-94. (Pubitemid 38352657)
5. Gillies PS, Dunn CJ. 2000. Pioglitazone. Drugs 60:333-343.
6. Grant AC, Ortiz-Coló n G, Doumit ME, Buskirk DD. 2008. Optimization of in vitro conditions for bovine subcutaneous and intramuscular preadipocyte differentiation. Journal of Animal Science 86:73-82.
7. Grant AC, Ortiz-Coló n G, Doumit ME, Tempelman RJ, Buskirk DD. 2008. Differentiation of bovine intramuscular and subcutaneous stromal-vascular cells exposed to dexamethasone and troglitazone. Journal of Animal Science 86:2531-2538.
8. Hausman GJ, Poulos SP, Pringle TD, Azain MJ. 2008. The influence of thiazolidinediones on adipogenesis in vitro and in vivo: potential modifiers of intramuscular adipose tissue deposition in meat animals. Journal of Animal Science 86:E236-E243.
9. Houseknecht KL, Cole BM, Steele PJ. 2002. Peroxisome proliferator- activated receptor gamma (PPARgamma) and its ligands: a review. Domestic Animal Endocrinology 22:1-23. (Pubitemid 34438654)
10. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. 2008. No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. British Journal of Clinical Pharmacology 65:78-86. (Pubitemid 350265174)
11. Kersten S, Desvergne B, Wahli W. 2000. Roles of PPARs in health and disease. Nature 405:421-424. (Pubitemid 30367411)
12. Kliewer SA, Xu HE, Lambert MH, Willson TM. 2001. Peroxisome proliferator-activated eceptors: from genes to physiology. Recent Progress in Hormone Research 56:239-265.
13. Knouff C, Auwerx J. 2004. Peroxisome proliferator-activated receptorg calls for activation in moderation: lessons from genetics and pharmacology. Endocrine Review 25:899-918. (Pubitemid 39657772)
14. Kushibiki S, Hodate K, Shingu H, Ueda Y, Shinoda M, Mori Y, Itoh T, Yokomizo Y. 2001. Insulin resistance induced in dairy steers by tumor necrosis factor alpha is partially reversed by 2,4-thiazolidinedione. Domestic Animal Endocrinology 21:25-37. (Pubitemid 32830444)
15. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptorg(PPARg). Journal of Biological Chemistry 270:12953-12956.
16. Mudaliar S, Henry RR. 2001. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annual Review of Medicine 52:239-257. (Pubitemid 32195323)
17. Poulos SP, Hausman GJ. 2006. A comparison of thiazolidinedione-induced adipogenesis and myogenesis in stromal vascular cells from subcutaneous adipose tissue or semitendinosus muscle of postnatal pigs. Journal of Animal Science 84:1076-1082. (Pubitemid 44405610)
18. Revelo XS, Waldron MR. 2010. Effects of in vitro insulin and 2,4-thiazolidinedione on the function of neutrophils harvested from blood of cows in different physiological states. Journal Dairy Science 93:3990-4005.
19. Smith KL, Butler WR, Overton TR. 2009. Effects of prepartum 2,4-thiazolidinedione on metabolism and performance in transition dairy cows. Journal Dairy Science 92:3623-3633.
20. Smith KL, Stebulis SE, Waldron MR, Overton TR. 2007. Prepartum 2,4-thiazolidinedione alters metabolic dynamics and dry matter intake of dairy cows. Journal Dairy Science 90:3660-3670. (Pubitemid 350045245)
21. Souri E, Jalalizadeh H, Saremi S. 2008. Development and validation of a simple and rapid HPLC method for determination of pioglitazone in human plasma and its application to a pharmacokinetic study. Journal of Chromatographic Science 46:809-812.
22. Tontonoz P, Spiegelman BM. 2008. Fat and beyond: the diverse biology of PPARg. Annual Review of Biochemistry 77:289-312.
23. Umathe SN, Dixit PV, Kumar V, Bansod KU, Wanjari MM. 2008. Quercetin pretreatment increases the bioavailability of pioglitazone in rats: involvement of CYP3A inhibition. Biochemical Pharmacology 75:1670-1676.
24. Wearn JMG, Crisman MV, Davis JL, Geor RJ, Hodgson DR, Suagee JK, Ashraf-khorassani M, McCutcheon LJ. 2010. Pharmacokinetics of pioglitazone after multiple oral dose administration in horses. Journal of veterinary Pharmacology and Therapeutics 34:252-258.
25. Yki-Jä rvinen H. 2004. Thiazolidinediones. New England Journal of Medicine 351:1106-1118.